Henry Schein (HSIC) 10-Q 3 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 26, 2021	Jul. 26, 2021
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-25
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 26, 2021
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		139,693,210

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Current assets:
Cash and cash equivalents	$ 167,228	$ 421,185
Accounts receivable, net of reserves of $81,113 and $88,030	1,356,881	1,424,787
Inventories, net	1,688,210	1,512,499
Prepaid expenses and other	529,929	432,944
Total current assets	3,742,248	3,791,415
Property and equipment, net	358,224	342,004
Operating lease right-of-use assets	301,440	288,847
Goodwill	2,722,974	2,504,392
Other intangibles, net	604,515	479,429
Investments and other	394,665	366,445
Total assets	8,124,066	7,772,532
Current liabilities:
Accounts payable	903,859	1,005,655
Bank credit lines	72,105	73,366
Current maturities of long-term debt	9,839	109,836
Operating lease liabilities	75,008	64,716
Accrued expenses:
Payroll and related	313,892	295,329
Taxes	156,176	138,671
Other	562,762	595,529
Total current liabilities	2,093,641	2,283,102
Total	706,487	515,773
Deferred income taxes	46,528	30,065
Operating lease liabilities	243,232	238,727
Other liabilities	423,416	392,781
Total liabilities	3,513,304	3,460,448
Redeemable noncontrolling interests	604,081	327,699
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized, 139,780,841 outstanding on June 26, 2021 and 142,462,571 outstanding on December 26, 2020	1,398	1,425
Additional paid-in capital	0	0
Retained earnings	3,465,647	3,454,831
Accumulated other comprehensive loss	(106,779)	(108,084)
Total Henry Schein, Inc. stockholders' equity	3,360,266	3,348,172
Noncontrolling interests	646,415	636,213
Total stockholders' equity	4,006,681	3,984,385
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 8,124,066	$ 7,772,532

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Current assets:
Accounts receivable, reserves (in dollars)	$ 81,113	$ 88,030
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	139,780,841	142,462,571

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
CONSOLIDATED STATEMENTS OF INCOME
Net sales	$ 2,967,223	$ 1,684,399	$ 5,892,184	$ 4,113,270
Cost of sales	2,077,472	1,230,133	4,111,582	2,912,990
Gross profit	889,751	454,266	1,780,602	1,200,280
Operating expenses:
Selling, general and administrative	678,801	445,765	1,336,793	1,013,127
Restructuring costs	604	15,934	3,535	20,721
Operating income (loss)	210,346	(7,433)	440,274	166,432
Other income (expense):
Interest income	1,357	1,997	3,340	5,187
Interest expense	(6,376)	(10,486)	(12,861)	(18,298)
Other, net	354	(291)	663	(511)
Income (loss) from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interest	205,681	(16,213)	431,416	152,810
Income tax benefit (expense)	(48,027)	950	(104,712)	(36,960)
Equity in earnings of affiliates	6,323	1,411	12,201	4,145
Net income (loss) from continuing operations	163,977	(13,852)	338,905	119,995
Income from discontinued operations, net of tax	0	585	0	303
Net income (loss)	163,977	(13,267)	338,905	120,298
Less: Net (income) loss attributable to noncontrolling interests	(8,261)	2,470	(17,192)	(834)
Plus: Net loss attributable to noncontrolling interests from discontinued operations	0	0	0	0
Net income (loss) attributable to Henry Schein, Inc.	155,716	(10,797)	321,713	119,464
Amounts attributable to Henry Schein Inc.: Continuing operations	155,716	(11,382)	321,713	119,161
Amounts attributable to Henry Schein Inc.: Discontinued operations	0	585	0	303
Net income (loss) attributable to Henry Schein, Inc.	$ 155,716	$ (10,797)	$ 321,713	$ 119,464
Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Diluted (in dollars per share)	0	0	0	0
Earnings (loss) per share from continuing operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	1.11	(0.08)	2.28	0.84
Diluted (in dollars per share)	1.10	(0.08)	2.26	0.84
Earnings (loss) per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	1.11	(0.08)	2.28	0.84
Diluted (in dollars per share)	$ 1.10	$ (0.08)	$ 2.26	$ 0.84
Weighted-average common shares outstanding:
Basic (in shares)	140,358	142,350	141,316	142,654
Diluted (in shares)	141,657	142,350	142,538	142,654

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 163,977	$ (13,267)	$ 338,905	$ 120,298
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	38,138	34,408	(343)	(54,904)
Unrealized gain (loss) from foreign currency hedging activities	(1,751)	(4,989)	1,610	10,154
Unrealized investment gain (loss)	3	2	(3)	(7)
Pension adjustment gain (loss)	35	(225)	842	499
Other comprehensive income (loss), net of tax	36,425	29,196	2,106	(44,258)
Comprehensive income	200,402	15,929	341,011	76,040
Comprehensive income attributable to noncontrolling interests:
Net income	(8,261)	2,470	(17,192)	(834)
Foreign currency translation (gain) loss	(6,899)	(799)	(801)	12,380
Comprehensive (income) loss attributable to noncontrolling interest	(15,160)	1,671	(17,993)	11,546
Comprehensive income attributable to Henry Schein, Inc.	$ 185,242	$ 17,600	$ 323,018	$ 87,586

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Common Stock [Member]	Common Stock [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Noncontrolling Interests [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Beginning Balance, shares (in shares) at Dec. 28, 2019				143,353,459
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase and retirement of common stock - Shares				(1,200,000)
Stock-based compensation credit - Shares				514,443
Shares withheld for payroll taxes - Shares				(229,775)
Settlement of stock-based compensation awards, shares				0
Ending Balance, shares (in shares) at Jun. 27, 2020				142,438,127
Beginning Balance at Dec. 28, 2019	$ 3,630,137	$ (412)		$ 1,434	$ 0		$ 47,768	$ 0		$ 3,116,215	$ (412)		$ (167,373)	$ 0		$ 632,093	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) (excluding amounts attributable to Redeemable noncontrolling interests from continuing operations)	119,137			0			0			119,464			0			(327)
Foreign currency translation loss (excluding amounts attributable to Redeemable noncontrolling interests)	(42,628)			0			0			0			(42,524)			(104)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	10,154			0			0			0			10,154			0
Unrealized investment gain (loss), net of tax impact	(7)			0			0			0			(7)			0
Pension adjustment gain, net of tax impact	499			0			0			0			499			0
Dividends paid	(507)			0			0			0			0			(507)
Purchase of noncontrolling interests	(2,298)			0			(1,597)			0			0			(701)
Change in fair value of redeemable securities	5,583			0			5,583			0			0			0
Initial noncontrolling interests and adjustments related to business acquisitions	4			0			0			0			0			4
Repurchase and retirement of common stock - Value	(73,789)			(12)			(10,949)			(62,828)			0			0
Stock-based compensation (credit) expense - Value	(12,358)			5			(12,363)			0			0			0
Shares withheld for payroll taxes - Value	(14,006)			(3)			(14,003)			0			0			0
Settlement of stock-based compensation awards, value	387			0			387			0			0			0
Separation of Animal Health business	1,649			0			1,649			0			0			0
Ending Balance at Jun. 27, 2020	3,621,545			$ 1,424			16,475			3,172,439			(199,251)			630,458
Beginning Balance, shares (in shares) at Mar. 28, 2020				142,433,360
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase and retirement of common stock - Shares				0
Stock-based compensation credit - Shares				7,033
Shares withheld for payroll taxes - Shares				(2,266)
Ending Balance, shares (in shares) at Jun. 27, 2020				142,438,127
Beginning Balance at Mar. 28, 2020	3,605,792			$ 1,424			17,565			3,183,236			(227,648)			631,215
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) (excluding amounts attributable to Redeemable noncontrolling interests from continuing operations)	(11,589)			0			0			(10,797)			0			(792)
Foreign currency translation loss (excluding amounts attributable to Redeemable noncontrolling interests)	33,657			0			0			0			33,609			48
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(4,989)			0			0			0			(4,989)			0
Unrealized investment gain (loss), net of tax impact	2			0			0			0			2			0
Pension adjustment gain, net of tax impact	(225)			0			0			0			(225)			0
Dividends paid	(8)			0			0			0			0			(8)
Purchase of noncontrolling interests	(9)			0			0			0			0			(9)
Change in fair value of redeemable securities	(7,489)			0			(7,489)			0			0			0
Initial noncontrolling interests and adjustments related to business acquisitions	4			0			0			0			0			4
Stock-based compensation (credit) expense - Value	5,156			0			5,156			0			0			0
Shares withheld for payroll taxes - Value	(132)			0			(132)			0			0			0
Settlement of stock-based compensation awards, value	(273)			0			(273)			0			0			0
Separation of Animal Health business	1,648			0			1,648			0			0			0
Ending Balance at Jun. 27, 2020	$ 3,621,545			$ 1,424			16,475			3,172,439			(199,251)			630,458
Beginning Balance, shares (in shares) at Dec. 26, 2020	142,462,571			142,462,571
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase and retirement of common stock - Shares				(2,867,557)
Stock issued upon exercise of stock options, shares	0
Stock-based compensation credit - Shares				299,561
Shares withheld for payroll taxes - Shares				(113,734)
Settlement of stock-based compensation awards, shares				0
Ending Balance, shares (in shares) at Jun. 26, 2021	139,780,841			139,780,841
Beginning Balance at Dec. 26, 2020	$ 3,984,385			$ 1,425			0			3,454,831			(108,084)			636,213
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) (excluding amounts attributable to Redeemable noncontrolling interests from continuing operations)	324,872			0			0			321,713			0			3,159
Foreign currency translation loss (excluding amounts attributable to Redeemable noncontrolling interests)	(913)			0			0			0			(1,144)			231
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	1,610			0			0			0			1,610			0
Unrealized investment gain (loss), net of tax impact	(3)			0			0			0			(3)			0
Pension adjustment gain, net of tax impact	842			0			0			0			842			0
Dividends paid	(154)			0			0			0			0			(154)
Change in fair value of redeemable securities	(132,708)			0			(132,708)			0			0			0
Initial noncontrolling interests and adjustments related to business acquisitions	6,966			0			0			0			0			6,966
Repurchase and retirement of common stock - Value	(201,211)			(29)			(27,241)			(173,941)			0			0
Stock-based compensation (credit) expense - Value	30,154			3			30,151			0			0			0
Shares withheld for payroll taxes - Value	(7,547)			(1)			(7,546)			0			0			0
Settlement of stock-based compensation awards, value	388			0			388			0			0			0
Transfer of charges in excess of capital			$ 0			$ 0			$ 136,956			$ (136,956)			$ 0			$ 0
Ending Balance at Jun. 26, 2021	$ 4,006,681			$ 1,398			0			3,465,647			(106,779)			646,415
Beginning Balance, shares (in shares) at Mar. 27, 2021				141,310,113
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase and retirement of common stock - Shares				(1,542,315)
Stock-based compensation credit - Shares				17,916
Shares withheld for payroll taxes - Shares				(4,873)
Ending Balance, shares (in shares) at Jun. 26, 2021	139,780,841			139,780,841
Beginning Balance at Mar. 27, 2021	$ 3,996,730			$ 1,413			0			3,493,060			(136,305)			638,562
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) (excluding amounts attributable to Redeemable noncontrolling interests from continuing operations)	156,997			0			0			155,716			0			1,281
Foreign currency translation loss (excluding amounts attributable to Redeemable noncontrolling interests)	31,395			0			0			0			31,239			156
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(1,751)			0			0			0			(1,751)			0
Unrealized investment gain (loss), net of tax impact	3			0			0			0			3			0
Pension adjustment gain, net of tax impact	35			0			0			0			35			0
Dividends paid	(77)			0			0			0			0			(77)
Change in fair value of redeemable securities	(87,188)			0			(87,188)			0			0			0
Initial noncontrolling interests and adjustments related to business acquisitions	6,493			0			0			0			0			6,493
Repurchase and retirement of common stock - Value	(112,552)			(15)			(14,992)			(97,545)			0			0
Stock-based compensation (credit) expense - Value	17,364			0			17,364			0			0			0
Shares withheld for payroll taxes - Value	(399)			0			(399)			0			0			0
Settlement of stock-based compensation awards, value	(369)			0			(369)			0			0			0
Transfer of charges in excess of capital	0			0			85,584			(85,584)			0			0
Ending Balance at Jun. 26, 2021	$ 4,006,681			$ 1,398			$ 0			$ 3,465,647			$ (106,779)			$ 646,415

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Statement of Stockholders' Equity [Abstract]
Unrealized loss from foreign currency hedging activities, tax (benefit)	$ 687	$ 1,744	$ (647)	$ (3,346)
Unrealized investment gain (loss), tax benefit (tax)	(1)	(1)	1	1
Pension adjustment gain, tax benefit (tax)	(38)	(125)	181	199
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to Redeemable noncontrolling interests			14,033
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	(6,743)	751	(570)	(12,276)
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to Redeemable noncontrolling interests	$ 6,980	$ 1,678	$ 14,033	$ 1,161

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Cash flows from operating activities:
Net income (loss)	$ 338,905	$ 120,298
Income from discontinued operations, net of tax	0	303
Income from continuing operations	338,905	119,995
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	99,278	93,946
Impairment charge on intangible assets	0	2,149
Stock-based compensation (credit) expense	30,154	(12,358)
Provision for (benefit from) losses on trade and other accounts receivable	(4,072)	28,758
Provision for (benefit from) deferred income taxes	5,705	(32,871)
Equity in earnings of affiliates	(12,201)	(4,145)
Distributions from equity affiliates	10,747	4,220
Changes in unrecognized tax benefits	(6,286)	1,380
Other	3,429	227
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	101,619	99,672
Inventories	(123,758)	13,700
Other current assets	(85,979)	(188,616)
Accounts payable and accrued expenses	(135,815)	(138,900)
Net cash provided by (used in) operating activities from continuing operations	221,726	(12,843)
Net cash provided by operating activities from discontinued operations	0	573
Net cash provided by (used in) operating activities	221,726	(12,270)
Cash flows from investing activities:
Purchases of fixed assets	(31,812)	(30,588)
Payments related to equity investments and business acquisitions, net of cash acquired	(295,652)	(37,725)
Proceeds from sale of equity investment	0	12,000
Payments for loan to affiliate	(2,021)	(1,729)
Other	(11,634)	(11,599)
Net cash used in investing activities from continuing operations	(341,119)	(69,641)
Net cash used in investing activities from discontinued operations	0	0
Net cash used in investing activities	(341,119)	(69,641)
Cash flows from financing activities:
Net change in bank borrowings	(5,381)	479,702
Proceeds from issuance of long-term debt	200,000	501,421
Principal payments for long-term debt	(120,326)	(609,580)
Debt issuance costs	(199)	(3,655)
Payments for repurchases of common stock	(201,211)	(73,789)
Payments for taxes related to shares withheld for employee taxes	(7,359)	(13,713)
Proceeds from (distributions to) noncontrolling shareholders	(3,789)	(3,466)
Acquisitions of noncontrolling interests in subsidiaries	(1,130)	(14,934)
Proceeds from Henry Schein Animal Health Business	0	64
Net cash provided by (used in) financing activities from continuing operations	(139,395)	262,050
Net cash provided by (used in) financing activities from discontinued operations	0	(573)
Net cash provided by (used in) operating activities	(139,395)	261,477
Effect of exchange rate changes on cash and cash equivalents- from continuing operations	4,831	10,447
Effect of exchange rate changes on cash and cash equivalents- from discontinued operations	0	0
Net change in cash and cash equivalents from continuing operations	(253,957)	190,013
Net change in cash and cash equivalents from discontinued operations	0	0
Net change in cash and cash equivalents	(253,957)	190,013
Cash and cash equivalents, beginning of period	421,185	106,097
Cash and cash equivalents, end of period	$ 167,228	$ 296,110

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 26, 2021
Basis of presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation. Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements. For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At June 26, 2021 and December 26, 2020, there were no trade accounts receivable that were restricted to settle obligations of this VIE, nor were there liabilities of the VIE where the creditors have recourse to us. The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 26, 2020. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the six months ended June 26, 2021 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 25, 2021. In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand increased in the second half of 2020 and has continued into the first half of 2021, resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products. Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows, primarily in the second quarter of 2020. In the latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and continued to do so during the second half of 2020. During the first half of 2021, patient traffic levels returned to levels approaching pre-pandemic levels. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

Critical Accounting Policies, A

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	6 Months Ended
	Jun. 26, 2021
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards Critical Accounting Policies There have been no material changes in our critical accounting policies during the six months ended June 26, 2021, as compared to the critical accounting policies described in Item 8 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 26, 2020, except as follows: Accounting Pronouncements Adopted In December 2019 adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 26, 2021
Revenue from Contracts with Customers
Revenue from Contracts with Customers	Note 3 – Revenue from Contracts with Customers Revenue is recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 26, 2020. Disaggregation of Revenue The following table disaggregates our revenue by segment and geography: Three Months Ended Six Months Ended June 26, 2021 June 26, 2021 North America International Global North America International Global Revenues: Health care distribution Dental $ 1,127,607 $ 782,737 $ 1,910,344 $ 2,172,390 $ 1,526,882 $ 3,699,272 Medical 877,773 27,055 904,828 1,842,900 54,965 1,897,865 Total health care distribution 2,005,380 809,792 2,815,172 4,015,290 1,581,847 5,597,137 Technology and value-added services 129,897 22,154 152,051 251,834 43,213 295,047 Total revenues $ 2,135,277 $ 831,946 $ 2,967,223 $ 4,267,124 $ 1,625,060 $ 5,892,184 Three Months Ended Six Months Ended June 27, 2020 June 27, 2020 North America International Global North America International Global Revenues: Health care distribution Dental $ 515,946 $ 425,346 $ 941,292 $ 1,404,318 $ 1,012,050 $ 2,416,368 Medical 596,588 21,222 617,810 1,374,616 43,882 1,418,498 Total health care distribution 1,112,534 446,568 1,559,102 2,778,934 1,055,932 3,834,866 Technology and value-added services 92,927 12,300 105,227 206,425 30,767 237,192 Total excluding Corporate TSA revenues (1) 1,205,461 458,868 1,664,329 2,985,359 1,086,699 4,072,058 Corporate TSA revenues (1) - 20,070 20,070 - 41,212 41,212 Total revenues $ 1,205,461 $ 478,938 $ 1,684,399 $ 2,985,359 $ 1,127,911 $ 4,113,270 Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. At December 26, 2020, the current portion of contract liabilities of $ 71.5 million was reported in Accrued expenses: Other, and $ 8.2 million related to non-current contract liabilities was reported in Other liabilities. During the six months ended June 26, 2021, we recognized in revenue $ 47.1 million of the amounts that were previously deferred at December 26, 2020. At June 26, 2021, the current and non-current portion of contract liabilities were $ 70.9 million and $ 9.0 million, respectively.

Segment Data

Segment Data	6 Months Ended
	Jun. 26, 2021
Segment Data
Segment Data	Note 4 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 32 countries worldwide. Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Net Sales: Health care distribution (1) Dental $ 1,910,344 $ 941,292 $ 3,699,272 $ 2,416,368 Medical 904,828 617,810 1,897,865 1,418,498 Total health care distribution 2,815,172 1,559,102 5,597,137 3,834,866 Technology and value-added services (2) 152,051 105,227 295,047 237,192 Total excluding Corporate TSA revenue 2,967,223 1,664,329 5,892,184 4,072,058 Corporate TSA revenues (3) - 20,070 - 41,212 Total $ 2,967,223 $ 1,684,399 $ 5,892,184 $ 4,113,270 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins. Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. See for further information. Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Operating Income (Loss): Health care distribution $ 181,761 $ ( 25,348) $ 379,693 $ 122,819 Technology and value-added services 28,585 17,915 60,581 43,613 Total $ 210,346 $ ( 7,433) $ 440,274 $ 166,432

Debt

Debt	6 Months Ended
	Jun. 26, 2021
Debt
Debt	Note 5 – Debt Bank Credit Lines Bank credit lines consisted of the following: June 26, December 26, 2021 2020 Revolving credit agreement $ - $ - Other short-term bank credit lines 72,105 73,366 Total $ 72,105 $ 73,366 Revolving Credit Agreement On April 18, 2017, we entered into a $ 750 million revolving credit agreement (the “Credit Agreement”), which matures in April 2022 9.3 million and $ 9.5 million of letters of credit, respectively, provided to third parties under the credit facility. On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021. 364-Day Credit Agreement On March 4, 2021, we repaid the outstanding obligations and terminated the lender commitments under our $ 700 million 364-day credit agreement which was entered into on April 17, 2020. This facility was originally scheduled to mature on April 16, 2021. Other Short-Term Credit Lines As of June 26, 2021 and December 26, 2020, we had various other short-term bank credit lines available, of which $ 72.1 million and $ 73.4 million, respectively, were outstanding. At June 26, 2021 and December 26, 2020, borrowings under all of these credit lines had a weighted average interest rate of 5.98% and 4.14%, respectively. Long-term debt Long-term debt consisted of the following: June 26, December 26, 2021 2020 Private placement facilities $ 706,332 $ 613,498 Note payable - 1,554 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 2.45% to 4.27% at June 26, 2021 and ranging from 2.62% to 4.27% at December 26, 2020 4,293 4,596 Finance lease obligations (see Note 6) 5,701 5,961 Total 716,326 625,609 Less current maturities ( 9,839) ( 109,836) Total long-term debt $ 706,487 $ 515,773 Private Placement Facilities Our private placement facilities, with three insurance companies, have a total facility amount of $ 1 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through June 23, 2023. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum maintenance total leverage ratio to 3.25x and remove the 1.00% interest rate increase triggered if the net leverage ratio were to exceed 3.0x. The components of our private placement facility borrowings as of June 26, 2021 are presented in the following table (in thousands): Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 (1) $ 7,143 3.09 % January 20, 2022 January 20, 2012 50,000 3.45 January 20, 2024 December 24, 2012 50,000 3.00 December 24, 2024 June 16, 2017 100,000 3.42 June 16, 2027 September 15, 2017 100,000 3.52 September 15, 2029 January 2, 2018 100,000 3.32 January 2, 2028 September 2, 2020 100,000 2.35 September 2, 2030 June 2, 2021 100,000 2.48 June 2, 2031 June 2, 2021 100,000 2.58 June 2, 2033 Less: Deferred debt issuance costs ( 811) $ 706,332 (1) Annual repayments of approximately $ 7.1 million for this borrowing commenced on January 20, 2016. U.S. Trade Accounts Receivable Securitization We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $ 350 million, was scheduled to expire on April 29, 2022. On June 22, 2020, the expiration date for this facility was extended to June 12, 2023 and was amended to adjust certain covenant levels for 2020. As of June 26, 2021 and December 26, 2020, there were no borrowings outstanding under this securitization facility. At June 26, 2021, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.14% plus 0.95%, for a combined rate of 1.09%. At December 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization.

Leases

Leases	6 Months Ended
	Jun. 26, 2021
Leases
Leases	Note 6 – Leases Leases We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment. Our leases have remaining terms of less than one year to approximately 15 years, some of which may include options to extend the leases for up to 10 years . The components of lease expense were as follows: Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Operating lease cost: (1) $ 25,840 $ 21,991 $ 48,946 $ 44,070 Finance lease cost: Amortization of right-of-use assets 516 282 1,120 714 Interest on lease liabilities 27 20 53 57 Total finance lease cost $ 543 $ 302 $ 1,173 $ 771 (1) Includes variable lease expenses. Supplemental balance sheet information related to leases is as follows: June 26, December 26, 2021 2020 Operating Leases: Operating lease right-of-use assets $ 301,440 $ 288,847 Current operating lease liabilities 75,008 64,716 Non-current operating lease liabilities 243,232 238,727 Total operating lease liabilities $ 318,240 $ 303,443 Finance Leases: Property and equipment, at cost $ 11,443 $ 10,683 Accumulated depreciation ( 5,170) ( 4,277) Property and equipment, net of accumulated depreciation $ 6,273 $ 6,406 Current maturities of long-term debt $ 2,420 $ 2,420 Long-term debt 3,281 3,541 Total finance lease liabilities $ 5,701 $ 5,961 Weighted Average Remaining Lease Term in Years: Operating leases 7.1 7.5 Finance leases 4.0 4.3 Weighted Average Discount Rate: Operating leases 2.6 % 2.8 % Finance leases 1.8 % 1.9 % Supplemental cash flow information related to leases is as follows: Six Months Ended June 26, June 27, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 39,988 $ 38,579 Operating cash flows for finance leases 47 50 Financing cash flows for finance leases 1,407 947 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 49,226 $ 14,926 Finance leases 1,244 1,814 Maturities of lease liabilities are as follows: June 26, 2021 Operating Finance Leases Leases 2021 $ 42,284 $ 1,384 2022 72,260 1,930 2023 49,569 963 2024 35,148 393 2025 30,519 337 Thereafter 118,761 895 Total future lease payments 348,541 5,902 Less: imputed interest ( 30,301) ( 201) Total $ 318,240 $ 5,701 As of June 26, 2021, we have additional operating leases with total lease payments of $ 12.5 million for buildings and vehicles that have not yet commenced. These operating leases will commence subsequent to June 26, 2021, with lease terms of two years to 10 years.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	6 Months Ended
	Jun. 26, 2021
Redeemable Noncontrolling Interests
Redeemable Noncontrolling Interests	Note 7 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the six months ended June 26, 2021 and the year ended December 26, 2020 are presented in the following table: June 26, December 26, 2021 2020 Balance, beginning of period $ 327,699 $ 287,258 Decrease in redeemable noncontrolling interests due to redemptions ( 1,130) ( 17,241) Increase in redeemable noncontrolling interests due to business acquisitions 140,155 28,387 Net income attributable to redeemable noncontrolling interests 14,033 13,363 Dividends declared ( 9,954) ( 12,631) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 570 ( 4,279) Change in fair value of redeemable securities 132,708 32,842 Balance, end of period $ 604,081 $ 327,699

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jun. 26, 2021
Comprehensive Income
Comprehensive Income	Note 8 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: June 26, December 26, 2021 2020 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ ( 24,047) $ ( 24,617) Attributable to noncontrolling interests: Foreign currency translation adjustment $ 466 $ 235 Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ ( 77,709) $ ( 76,565) Unrealized loss from foreign currency hedging activities ( 9,878) ( 11,488) Unrealized investment gain (loss) ( 2) 1 Pension adjustment loss ( 19,190) ( 20,032) Accumulated other comprehensive loss $ ( 106,779) $ ( 108,084) Total Accumulated other comprehensive loss $ ( 130,360) $ ( 132,466) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Net income (loss) $ 163,977 $ ( 13,267) $ 338,905 $ 120,298 Foreign currency translation gain (loss) 38,138 34,408 ( 343) ( 54,904) Tax effect - - - - Foreign currency translation gain (loss) 38,138 34,408 ( 343) ( 54,904) Unrealized gain (loss) from foreign currency hedging activities ( 2,438) ( 6,733) 2,257 13,500 Tax effect 687 1,744 ( 647) ( 3,346) Unrealized gain (loss) from foreign currency hedging activities ( 1,751) ( 4,989) 1,610 10,154 Unrealized investment gain (loss) 4 3 ( 4) ( 8) Tax effect ( 1) ( 1) 1 1 Unrealized investment gain (loss) 3 2 ( 3) ( 7) Pension adjustment gain (loss) ( 3) ( 350) 1,023 698 Tax effect 38 125 ( 181) ( 199) Pension adjustment gain (loss) 35 ( 225) 842 499 Comprehensive income $ 200,402 $ 15,929 $ 341,011 $ 76,040 The change in the unrealized gain (loss) from foreign currency hedging activities during the three months and year ended June 26, 2021, compared to the comparable prior year period, was primarily attributable to a net investment hedge that was entered into during 2019. See for further information. Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the six months ended June 26, 2021 and six months ended June 27, 2020 was primarily impacted by changes in foreign currency exchange rates of the Euro, British Pound, Brazilian Real, Australian Dollar and Canadian Dollar. The following table summarizes our total comprehensive income, net of applicable taxes, as follows: Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Comprehensive income attributable to Henry Schein, Inc. $ 185,242 $ 17,600 $ 323,018 $ 87,586 Comprehensive income (loss) attributable to noncontrolling interests 1,437 ( 744) 3,390 ( 431) Comprehensive income (loss) attributable to Redeemable noncontrolling interests 13,723 ( 927) 14,603 ( 11,115) Comprehensive income $ 200,402 $ 15,929 $ 341,011 $ 76,040

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 26, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy as of June 26, 2021 and December 26, 2020 was estimated at $ 788.4 million and $ 699.0 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan and our deferred compensation plan. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. See for further information. Redeemable noncontrolling interests The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. See for additional information. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 26, 2021 and December 26, 2020: June 26, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,471 $ - $ 1,471 Total return swaps - 1,317 - 1,317 Total assets $ - $ 2,788 $ - $ 2,788 Liabilities: Derivative contracts $ - $ 9,542 $ - $ 9,542 Total liabilities $ - $ 9,542 $ - $ 9,542 Redeemable noncontrolling interests $ - $ - $ 604,081 $ 604,081 December 26, 2020 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,868 $ - $ 1,868 Total return swaps - 1,565 - 1,565 Total assets $ - $ 3,433 $ - $ 3,433 Liabilities: Derivative contracts $ - $ 11,765 $ - $ 11,765 Total liabilities $ - $ 11,765 $ - $ 11,765 Redeemable noncontrolling interests $ - $ - $ 327,699 $ 327,699

Business Acquisitions

Business Acquisitions	6 Months Ended
	Jun. 26, 2021
Business Acquisitions
Business Acquisitions	Note 10 – Business Acquisitions Acquisitions We completed acquisitions during the six months ended June 26, 2021 which were immaterial to our financial statements. The acquisitions that we completed included companies within our Health care distribution and Technology and value-added services segments. The initial ownership interest we acquired in these companies ranged from approximately 51% to 100%. Acquisitions within our Health care distribution segment included companies that specialize in the distribution of dental products, a provider of home medical supplies, and a provider of product kitting and sterile packaging. Within our Technology and value-added services segment, we acquired companies that focus on dental marketing and website solutions, practice transition services, and business analytics and intelligence software. The following table summarizes the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the six months ended June 26, 2021. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. Acquisition consideration: Cash $ 310,523 Redeemable noncontrolling interests 129,319 Total consideration 439,842 Identifiable assets acquired and liabilities assumed: Current assets 107,197 Intangible assets 183,796 Other noncurrent assets 33,959 Current liabilities ( 43,781) Deferred income taxes ( 17,442) Other noncurrent liabilities ( 37,462) Total identifiable net assets 226,267 Goodwill 213,575 Total net assets acquired $ 439,842 The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from analysis of market conditions, discount rates, discounted cash flows, customer retention rates and estimated useful lives. Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the six months ended June 26, 2021 and June 27, 2020, there were no material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent purchase price liabilities.

Plans of Restructuring

Plans of Restructuring	6 Months Ended
	Jun. 26, 2021
Plans of Restructuring [Abstract]
Plans of Restructuring	Note 11 – Plans of Restructuring On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities were originally expected to be completed by the end of 2020. In light of the changes to the business environment brought on by the COVID-19 pandemic, we extended such activities to the end of 2021. During the three months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $ 0.6 million and $ 15.9 million. During the six months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $ 3.5 million and $ 20.7 million. The restructuring costs for these periods included costs for severance benefits and facility exit costs. The costs associated with these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. The following table shows the net amounts expensed and paid for restructuring costs that were incurred during the six months ended June 26, 2021 and during our 2020 fiscal year and the remaining accrued balance of restructuring costs as of June 26, 2021, which is included in Accrued expenses: Other within our consolidated balance sheets: Facility Severance Closing Costs Costs Other Total Balance, December 28, 2019 $ 12,911 $ 826 $ 73 $ 13,810 Provision 25,855 5,878 360 32,093 Payments and other adjustments ( 26,152) ( 6,309) ( 329) ( 32,790) Balance, December 26, 2020 $ 12,614 $ 395 $ 104 $ 13,113 Provision 3,436 ( 122) 221 3,535 Payments and other adjustments ( 12,736) 50 ( 321) ( 13,007) Balance, June 26, 2021 $ 3,314 $ 323 $ 4 $ 3,641 The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that were incurred during the six months ended June 26, 2021 and during our 2020 fiscal year and the remaining accrued balance of restructuring costs as of June 26, 2021: Technology and Health Care Value-Added Distribution Services Total Balance, December 28, 2019 $ 13,373 $ 437 $ 13,810 Provision 30,935 1,158 32,093 Payments and other adjustments ( 31,484) ( 1,306) ( 32,790) Balance, December 26, 2020 $ 12,824 $ 289 $ 13,113 Provision 3,082 453 3,535 Payments and other adjustments ( 12,561) ( 446) ( 13,007) Balance, June 26, 2021 $ 3,345 $ 296 $ 3,641

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 26, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Note 12 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Basic 140,358 142,350 141,316 142,654 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 1,299 - 1,222 - Diluted 141,657 142,350 142,538 142,654

Income Taxes

Income Taxes	6 Months Ended
	Jun. 26, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes For the six months ended June 26, 2021 our effective tax rate was 24.3% compared to 24.2% for the prior year period. The difference between our effective tax rates and the federal statutory tax rate for the six months ended June 26, 2021 primarily relates to state and foreign income taxes, interest expense and tax charges and credits associated with legal entity reorganizations. The difference between our effective tax rate and the federal statutory tax rate for the six months ended June 27, 2020 primarily relates to state and foreign income taxes and interest expense, tax charges and credits associated with legal entity reorganizations outside the U.S and a valuation allowance recognized on a portion of a deferred tax asset. The American Rescue Plan Act of 2021 (“ARPA”) was signed into law on March 11, 2021. The ARPA included a corporate income tax provision to further limit the deductibility of compensation under Section 162(m) for tax years starting after December 31, 2026. Section 162(m) generally limits the deductibility of compensation paid to covered employees of publicly held corporations. Covered employees include the CEO, CFO and the three highest paid officers. The ARPA expands the group of covered employees to additionally include five of the highest paid employees. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax provisions that modify the Section 163(j) limitation of business interest and net operating loss carryover and carryback rules. We have analyzed the income tax provisions of the CARES Act and have accounted for the impact in the six months ended June 27, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to us under the CARES Act that require further clarification or interpretation that may affect our consolidated financial statements in the future. The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets, as of June 26, 2021 was approximately $ 79.3 million, of which $ 63.9 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated statements of income. The tax years subject to examination by major tax jurisdictions include years 2017 and forward by the U.S Internal Revenue Service (the “IRS”) as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2016. During the quarter ended June 26, 2021 we reached a resolution with the Appellate Division for all remaining outstanding issues for 2012 and 2013. The resolution did not have a material impact to our consolidated financial statements. We reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and 2013 in the quarter ended December 28, 2019. During the quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution was to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a favorable resolution with the IRS relating to select audit years. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense/(credit) was approximately $( 2.7) million for the six months ended June 26, 2021, and $ 1.8 million for the six months ended June 27, 2020. The total amount of accrued interest is included in “Other liabilities,” and was approximately $ 11.3 million as of June 26, 2021 and $ 14.0 million as of December 26, 2020. No penalties were accrued for the periods presented.

Derivatives and Hedging Activit

Derivatives and Hedging Activities	6 Months Ended
	Jun. 26, 2021
Derivative and Hedging Activities [Abstract]
Derivatives and Hedging Activities	Note 14 – Derivatives and Hedging Activities We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital. During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023, is approximately € 200 million. During the three months ended June 26, 2021 and June 27, 2020, we recognized approximately $ 1.1 million and $ 1.2 million, respectively, of interest savings as a result of this net investment hedge. During the six months ended June 26, 2021 and June 27, 2020, we recognized approximately $ 2.2 and $ 2.4 million, respectively, of interest savings as a result of this net investment hedge. On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $ 43.4 million. At June 26, 2021, the notional value of the investments in these plans was $ 84.8 million. At June 26, 2021, the financing blended rate for this swap was based on LIBOR of 0.09% plus 0.47%, for a combined rate of 0.56%. For the three months and six months ended June 26, 2021, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $ 5.4 million and $ 8.1 million, respectively, net of transaction costs, related to this undesignated swap. For the three months and six months ended June 27, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $ 6.7 million and $ 10.3 million, respectively, net of transaction costs, related to this undesignated swap. This swap is expected to be renewed on an annual basis after its current expiration date of March 29, 2022, and is expected to result in a neutral impact to our results of operations. Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 26, 2021
Disclosure of Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 15 – Stock-Based Compensation Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $ 17.4 million ($ 13.3 million after-tax) and $ 30.2 million ($ 22.8 million after-tax) for the three and six months ended June 26, 2021, respectively. For the three and six months ended June 27, 2020 we recorded pre-tax share-based compensation expense of $ 5.2 million ($ 4.2 million after-tax) and a credit of $ 12.4 million ($ 9.4 million after-tax), respectively. The $ 12.4 million credit for share-based compensation during the six months ended June 27, 2020 reflected our reduced estimate in expected achievement of performance-based targets resulting from the impact of COVID-19. Our accompanying consolidated statements of cash flows present our stock-based compensation expense (credit) as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the six months ended June 26, 2021 and June 27, 2020, respectively. Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income. Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020 Stock Incentive Plan and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards have been granted solely in the form of restricted stock units (“RSUs”). However, beginning in 2021, our equity-based awards have been granted in the form of RSUs and non-qualified stock options. Grants of RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. We issue RSUs that vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily 12-month cliff vesting), and RSUs that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily three-year During the three months ended March 27, 2021, as a result of the continuing economic risk and uncertainty resulting from the ongoing COVID-19 pandemic, the Compensation Committee decided to adjust the form of awards granted under our 2021 long-term incentive program for our 2021 fiscal year in a manner that focuses on our long-term value by granting stock options and time-based RSUs rather than performance-based RSUs. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued during 2021 vest one-third three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimate the fair value of stock options using the Black-Scholes valuation model. In addition to equity-based awards under the 2021 long-term incentive program under the 2020 Stock Incentive Plan, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. These awards will vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date and are recorded as compensation expense using a graded vesting method. With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. The Plans provide for adjustments to the performance-based restricted stock units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets and foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. Total unrecognized compensation cost related to unvested awards as of June 26, 2021 was $ 99.0 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years. The following weighted-average assumptions were used in determining the most recent fair values of stock options using the Black-Scholes valuation model: Expected dividend yield 0.0 % Expected stock price volatility 26.60 % Risk-free interest rate 0.94 % Expected life of options (years) 6.00 We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The 6 -year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us. The following table summarizes stock option activity under the Plans during the six months ended June 26, 2021: Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Life in Intrinsic Shares Price Years Value Outstanding at beginning of period - $ - Granted 794 62.82 Exercised - - Forfeited ( 2) 62.71 Outstanding at end of period 792 $ 62.82 9.7 $ 12.21 Options exercisable at end of period 1 $ - - $ - The following tables summarize the activity of our unvested RSUs for the six months ended June 26, 2021: Time-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,459 $ 57.61 Granted 821 63.02 Vested ( 266) 66.85 Forfeited ( 19) 60.47 Outstanding at end of period 1,995 $ 58.64 $ 75.01 Performance-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 136 $ 53.52 Granted 286 58.60 Vested ( 83) 52.30 Forfeited ( 9) 59.46 Outstanding at end of period 330 $ 59.50 $ 75.01

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 26, 2021
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 16 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Six Months Ended June 26, June 27, 2021 2020 Interest $ 13,605 $ 16,925 Income taxes 134,232 31,553 During the six months ended June 26, 2021 and June 27, 2020, we had a $ 2.3 million and $ 13.5 million of non-cash net unrealized gains related to foreign currency hedging activities, respectively.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 26, 2021
Legal Proceedings [Abstract]
Legal Proceedings	Note 17 – Legal Proceedings On August 31, 2012 Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleged a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017 Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer sought damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017 Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action were the same as the August 1, 2017 amended complaint. On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020. Archer conditionally cross petitioned for certiorari on an arbitration issue on March 2, 2020. On June 15, 2020, the Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional petition for certiorari, and thus the District Court proceedings remained stayed. After briefing from the parties and several amici, the case was argued before the Supreme Court on December 8, 2020. On January 25, 2021, the Supreme Court dismissed the writ of certiorari as improvidently granted. That action dissolved the stay the Supreme Court had previously granted. The U.S. District Court for the Eastern District of Texas then set the case for trial, and jury selection was scheduled to begin on June 1, 2021. Patterson and the Danaher Defendants settled with Archer and they have been dismissed from the case with prejudice. Benco settled the case with the plaintiff. Henry Schein and the plaintiff settled this matter for an amount that is not material to the Company. The court dismissed the case with prejudice on May 25, 2021. On May 29, 2018 The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $ 1 million to a foundation and paid $ 250,000 of Summit County’s expenses, as described in our prior filings with the SEC. In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty ( 150)), which allege claims similar to those alleged in the County of Summit Action. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court gave plaintiffs until November 24, 2020 to replead their claims against Henry Schein. On January 8, 2021, Henry Schein filed a motion to dismiss the Amended Complaint. By Order entered on March 24, 2021, the Circuit Court of Washington County, Arkansas, Case No. 72-CV20-156, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by Fayetteville Arkansas Hospital Company, LLC, et al. The Arkansas plaintiffs filed an amended complaint on July 29, 2021and did not name Henry Schein as a defendant. An action filed by Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated that trial date. At this time, the only cases set for trial are the actions filed by West Virginia University Hospitals, Inc. et al., which is currently scheduled for a non-jury liability trial on plaintiffs’ public nuisance claims on November 1, 2021, and DCH Health Care Authority, et al., which is currently scheduled for a liability jury trial on plaintiffs’ public nuisance claims on July 18, 2022. Of Henry Schein’s 2020 revenue of approximately $ 10.1 billion from continuing operations, sales of opioids represented less than one-tenth of 1 On September 30, 2019 City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading On February 5, 2021 Jack Garnsey filed a putative shareholder derivative action on behalf of Covetrus, Inc. in the U.S. District Court for the Eastern District of New York, naming as defendants Benjamin Shaw, Christine T. Komola, Steven Paladino, Betsy Atkins, Deborah G. Ellinger, Sandra L. Helton, Philip A. Laskaway, Mark J. Manoff, Edward M. McNamara, Ravi Sachdev, David E. Shaw, Benjamin Wolin, and Henry Schein, Inc., with Covetrus, Inc. named as a nominal defendant. The complaint alleges that the individual defendants breached their fiduciary duties under state law in connection with the same allegations asserted in the City of Hollywood securities class action described above and further alleges that Henry Schein aided and abetted such breaches. The complaint also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants, also arising out of the allegations in the City of Hollywood lawsuit. The complaint seeks declaratory, injunctive, and monetary relief. We intend to defend ourselves vigorously against this action. On April 8, 2021 the Court entered an order staying the Garnsey action until forty-five ( 45) days after a decision is issued finally resolving the motions to dismiss in the City of Hollywood Class Action. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of June 26, 2021, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 26, 2021
Related Party Transactions
Related Party Transactions	Note 18 – Related Party Transactions On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus. In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $ 1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors for $ 361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a transition services agreement with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. Services provided under this transition services agreement ended in December 2020. During the three and six months ended June 27, 2020, we recorded approximately $ 4.3 million and $ 8.8 million, respectively, of fees for these services. Covetrus also purchased certain products from us pursuant to the transition services agreement, which ended in December 2020. During the three and six months ended June 27, 2020, net sales to Covetrus were approximately $ 20.1 million and $ 41.2 million, respectively. In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31.0 million annually for the use of their intellectual property. 7.8 million and $ 15.6 million, respectively in connection with costs related to this royalty agreement. During the three and six months ended June 27, 2020, we recorded $ 7.8 million and $ 15.6 million, respectively in connection with costs related to this royalty agreement. As of June 26, 2021 and December 26, 2020, Henry Schein One, LLC had a net (payable) receivable balance due (to) from Internet Brands of $( 6.3) million and $ 4.7 million, respectively, comprised of amounts related to results of operations and the royalty agreement. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three and six months ended June 26, 2021, we recorded net sales of $ 18.0 million and $ 33.4 million, respectively, to such entities. During the three and six months ended June 27, 2020, we recorded net sales of $ 9.1 million and $ 24.5 million, respectively, to such entities. During the three and six months ended June 26, 2021, we purchased $ 5.3 million and $ 9.1 million, respectively, from such entities. During the three and six months ended June 27, 2020, we purchased $ 1.7 million and $ 4.5 million, respectively, from such entities. At June 26, 2021 and December 26, 2020, in the aggregate we had $ 42.0 million and $ 36.4 million, due from our equity affiliates, and $ 10.1 million and $ 8.6 million due to our equity affiliates, respectively.

Critical Accounting Policies,_2

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards (Policies)	6 Months Ended
	Jun. 26, 2021
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards
Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Accounting Pronouncements Adopted In December 2019 adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 26, 2021
Revenue from Contracts with Customers
Disaggregation of Revenue	Three Months Ended Six Months Ended June 26, 2021 June 26, 2021 North America International Global North America International Global Revenues: Health care distribution Dental $ 1,127,607 $ 782,737 $ 1,910,344 $ 2,172,390 $ 1,526,882 $ 3,699,272 Medical 877,773 27,055 904,828 1,842,900 54,965 1,897,865 Total health care distribution 2,005,380 809,792 2,815,172 4,015,290 1,581,847 5,597,137 Technology and value-added services 129,897 22,154 152,051 251,834 43,213 295,047 Total revenues $ 2,135,277 $ 831,946 $ 2,967,223 $ 4,267,124 $ 1,625,060 $ 5,892,184 Three Months Ended Six Months Ended June 27, 2020 June 27, 2020 North America International Global North America International Global Revenues: Health care distribution Dental $ 515,946 $ 425,346 $ 941,292 $ 1,404,318 $ 1,012,050 $ 2,416,368 Medical 596,588 21,222 617,810 1,374,616 43,882 1,418,498 Total health care distribution 1,112,534 446,568 1,559,102 2,778,934 1,055,932 3,834,866 Technology and value-added services 92,927 12,300 105,227 206,425 30,767 237,192 Total excluding Corporate TSA revenues (1) 1,205,461 458,868 1,664,329 2,985,359 1,086,699 4,072,058 Corporate TSA revenues (1) - 20,070 20,070 - 41,212 41,212 Total revenues $ 1,205,461 $ 478,938 $ 1,684,399 $ 2,985,359 $ 1,127,911 $ 4,113,270 Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jun. 26, 2021
Segment Data
Business segment information	Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Net Sales: Health care distribution (1) Dental $ 1,910,344 $ 941,292 $ 3,699,272 $ 2,416,368 Medical 904,828 617,810 1,897,865 1,418,498 Total health care distribution 2,815,172 1,559,102 5,597,137 3,834,866 Technology and value-added services (2) 152,051 105,227 295,047 237,192 Total excluding Corporate TSA revenue 2,967,223 1,664,329 5,892,184 4,072,058 Corporate TSA revenues (3) - 20,070 - 41,212 Total $ 2,967,223 $ 1,684,399 $ 5,892,184 $ 4,113,270 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins. Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. See for further information. Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Operating Income (Loss): Health care distribution $ 181,761 $ ( 25,348) $ 379,693 $ 122,819 Technology and value-added services 28,585 17,915 60,581 43,613 Total $ 210,346 $ ( 7,433) $ 440,274 $ 166,432

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 26, 2021
Debt
Bank credit lines	June 26, December 26, 2021 2020 Revolving credit agreement $ - $ - Other short-term bank credit lines 72,105 73,366 Total $ 72,105 $ 73,366
Long-term debt	June 26, December 26, 2021 2020 Private placement facilities $ 706,332 $ 613,498 Note payable - 1,554 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 2.45% to 4.27% at June 26, 2021 and ranging from 2.62% to 4.27% at December 26, 2020 4,293 4,596 Finance lease obligations (see Note 6) 5,701 5,961 Total 716,326 625,609 Less current maturities ( 9,839) ( 109,836) Total long-term debt $ 706,487 $ 515,773
Private placement facilities	Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 (1) $ 7,143 3.09 % January 20, 2022 January 20, 2012 50,000 3.45 January 20, 2024 December 24, 2012 50,000 3.00 December 24, 2024 June 16, 2017 100,000 3.42 June 16, 2027 September 15, 2017 100,000 3.52 September 15, 2029 January 2, 2018 100,000 3.32 January 2, 2028 September 2, 2020 100,000 2.35 September 2, 2030 June 2, 2021 100,000 2.48 June 2, 2031 June 2, 2021 100,000 2.58 June 2, 2033 Less: Deferred debt issuance costs ( 811) $ 706,332 (1) Annual repayments of approximately $ 7.1 million for this borrowing commenced on January 20, 2016.

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 26, 2021
Leases
Components of lease expense, supplemental balance sheet information, and supplemental cash flow	Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Operating lease cost: (1) $ 25,840 $ 21,991 $ 48,946 $ 44,070 Finance lease cost: Amortization of right-of-use assets 516 282 1,120 714 Interest on lease liabilities 27 20 53 57 Total finance lease cost $ 543 $ 302 $ 1,173 $ 771 (1) Includes variable lease expenses. Supplemental balance sheet information related to leases is as follows: June 26, December 26, 2021 2020 Operating Leases: Operating lease right-of-use assets $ 301,440 $ 288,847 Current operating lease liabilities 75,008 64,716 Non-current operating lease liabilities 243,232 238,727 Total operating lease liabilities $ 318,240 $ 303,443 Finance Leases: Property and equipment, at cost $ 11,443 $ 10,683 Accumulated depreciation ( 5,170) ( 4,277) Property and equipment, net of accumulated depreciation $ 6,273 $ 6,406 Current maturities of long-term debt $ 2,420 $ 2,420 Long-term debt 3,281 3,541 Total finance lease liabilities $ 5,701 $ 5,961 Weighted Average Remaining Lease Term in Years: Operating leases 7.1 7.5 Finance leases 4.0 4.3 Weighted Average Discount Rate: Operating leases 2.6 % 2.8 % Finance leases 1.8 % 1.9 % Supplemental cash flow information related to leases is as follows: Six Months Ended June 26, June 27, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 39,988 $ 38,579 Operating cash flows for finance leases 47 50 Financing cash flows for finance leases 1,407 947 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 49,226 $ 14,926 Finance leases 1,244 1,814
Maturities of operating lease liabilities	Maturities of lease liabilities are as follows: June 26, 2021 Operating Finance Leases Leases 2021 $ 42,284 $ 1,384 2022 72,260 1,930 2023 49,569 963 2024 35,148 393 2025 30,519 337 Thereafter 118,761 895 Total future lease payments 348,541 5,902 Less: imputed interest ( 30,301) ( 201) Total $ 318,240 $ 5,701
Maturities of finance lease liabilities	Maturities of lease liabilities are as follows: June 26, 2021 Operating Finance Leases Leases 2021 $ 42,284 $ 1,384 2022 72,260 1,930 2023 49,569 963 2024 35,148 393 2025 30,519 337 Thereafter 118,761 895 Total future lease payments 348,541 5,902 Less: imputed interest ( 30,301) ( 201) Total $ 318,240 $ 5,701

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 26, 2021
Redeemable Noncontrolling Interests
Change in fair value of redeemable noncontrolling interests	June 26, December 26, 2021 2020 Balance, beginning of period $ 327,699 $ 287,258 Decrease in redeemable noncontrolling interests due to redemptions ( 1,130) ( 17,241) Increase in redeemable noncontrolling interests due to business acquisitions 140,155 28,387 Net income attributable to redeemable noncontrolling interests 14,033 13,363 Dividends declared ( 9,954) ( 12,631) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 570 ( 4,279) Change in fair value of redeemable securities 132,708 32,842 Balance, end of period $ 604,081 $ 327,699

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jun. 26, 2021
Comprehensive Income
Accumulated other comprehensive loss net of applicable taxes	June 26, December 26, 2021 2020 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ ( 24,047) $ ( 24,617) Attributable to noncontrolling interests: Foreign currency translation adjustment $ 466 $ 235 Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ ( 77,709) $ ( 76,565) Unrealized loss from foreign currency hedging activities ( 9,878) ( 11,488) Unrealized investment gain (loss) ( 2) 1 Pension adjustment loss ( 19,190) ( 20,032) Accumulated other comprehensive loss $ ( 106,779) $ ( 108,084) Total Accumulated other comprehensive loss $ ( 130,360) $ ( 132,466)
Components of comprehensive income, net of applicable taxes	Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Net income (loss) $ 163,977 $ ( 13,267) $ 338,905 $ 120,298 Foreign currency translation gain (loss) 38,138 34,408 ( 343) ( 54,904) Tax effect - - - - Foreign currency translation gain (loss) 38,138 34,408 ( 343) ( 54,904) Unrealized gain (loss) from foreign currency hedging activities ( 2,438) ( 6,733) 2,257 13,500 Tax effect 687 1,744 ( 647) ( 3,346) Unrealized gain (loss) from foreign currency hedging activities ( 1,751) ( 4,989) 1,610 10,154 Unrealized investment gain (loss) 4 3 ( 4) ( 8) Tax effect ( 1) ( 1) 1 1 Unrealized investment gain (loss) 3 2 ( 3) ( 7) Pension adjustment gain (loss) ( 3) ( 350) 1,023 698 Tax effect 38 125 ( 181) ( 199) Pension adjustment gain (loss) 35 ( 225) 842 499 Comprehensive income $ 200,402 $ 15,929 $ 341,011 $ 76,040
Total comprehensive income, net of applicable taxes	Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Comprehensive income attributable to Henry Schein, Inc. $ 185,242 $ 17,600 $ 323,018 $ 87,586 Comprehensive income (loss) attributable to noncontrolling interests 1,437 ( 744) 3,390 ( 431) Comprehensive income (loss) attributable to Redeemable noncontrolling interests 13,723 ( 927) 14,603 ( 11,115) Comprehensive income $ 200,402 $ 15,929 $ 341,011 $ 76,040

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 26, 2021
Fair Value Disclosures [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	June 26, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,471 $ - $ 1,471 Total return swaps - 1,317 - 1,317 Total assets $ - $ 2,788 $ - $ 2,788 Liabilities: Derivative contracts $ - $ 9,542 $ - $ 9,542 Total liabilities $ - $ 9,542 $ - $ 9,542 Redeemable noncontrolling interests $ - $ - $ 604,081 $ 604,081 December 26, 2020 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,868 $ - $ 1,868 Total return swaps - 1,565 - 1,565 Total assets $ - $ 3,433 $ - $ 3,433 Liabilities: Derivative contracts $ - $ 11,765 $ - $ 11,765 Total liabilities $ - $ 11,765 $ - $ 11,765 Redeemable noncontrolling interests $ - $ - $ 327,699 $ 327,699

Business Acquisitions (Tables)

Business Acquisitions (Tables)	6 Months Ended
	Jun. 26, 2021
Business Acquisitions
Summary of estimated fair value, Acquisitions consideration	Acquisition consideration: Cash $ 310,523 Redeemable noncontrolling interests 129,319 Total consideration 439,842 Identifiable assets acquired and liabilities assumed: Current assets 107,197 Intangible assets 183,796 Other noncurrent assets 33,959 Current liabilities ( 43,781) Deferred income taxes ( 17,442) Other noncurrent liabilities ( 37,462) Total identifiable net assets 226,267 Goodwill 213,575 Total net assets acquired $ 439,842

Plans of Restructuring (Tables)

Plans of Restructuring (Tables)	6 Months Ended
	Jun. 26, 2021
Plans of Restructuring [Abstract]
Schedule of restructuring reserve by type of cost	Facility Severance Closing Costs Costs Other Total Balance, December 28, 2019 $ 12,911 $ 826 $ 73 $ 13,810 Provision 25,855 5,878 360 32,093 Payments and other adjustments ( 26,152) ( 6,309) ( 329) ( 32,790) Balance, December 26, 2020 $ 12,614 $ 395 $ 104 $ 13,113 Provision 3,436 ( 122) 221 3,535 Payments and other adjustments ( 12,736) 50 ( 321) ( 13,007) Balance, June 26, 2021 $ 3,314 $ 323 $ 4 $ 3,641
Schedule of restructuring reserve by segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 28, 2019 $ 13,373 $ 437 $ 13,810 Provision 30,935 1,158 32,093 Payments and other adjustments ( 31,484) ( 1,306) ( 32,790) Balance, December 26, 2020 $ 12,824 $ 289 $ 13,113 Provision 3,082 453 3,535 Payments and other adjustments ( 12,561) ( 446) ( 13,007) Balance, June 26, 2021 $ 3,345 $ 296 $ 3,641

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 26, 2021
Earnings Per Share [Abstract]
Reconciliation of basic and diluted shares used to calculate earnings per share	Three Months Ended Six Months Ended June 26, June 27, June 26, June 27, 2021 2020 2021 2020 Basic 140,358 142,350 141,316 142,654 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 1,299 - 1,222 - Diluted 141,657 142,350 142,538 142,654

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 26, 2021
Disclosure of Stock-Based Compensation [Abstract]
Assumptions used in determining fair values of stock options using the Black-Scholes valuation model	Expected dividend yield 0.0 % Expected stock price volatility 26.60 % Risk-free interest rate 0.94 % Expected life of options (years) 6.00
Summary of stock option activity under the Plans	Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Life in Intrinsic Shares Price Years Value Outstanding at beginning of period - $ - Granted 794 62.82 Exercised - - Forfeited ( 2) 62.71 Outstanding at end of period 792 $ 62.82 9.7 $ 12.21 Options exercisable at end of period 1 $ - - $ -
Status of non-vested restricted shares/units	Time-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,459 $ 57.61 Granted 821 63.02 Vested ( 266) 66.85 Forfeited ( 19) 60.47 Outstanding at end of period 1,995 $ 58.64 $ 75.01 Performance-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 136 $ 53.52 Granted 286 58.60 Vested ( 83) 52.30 Forfeited ( 9) 59.46 Outstanding at end of period 330 $ 59.50 $ 75.01

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 26, 2021
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Six Months Ended June 26, June 27, 2021 2020 Interest $ 13,605 $ 16,925 Income taxes 134,232 31,553

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) - USD ($)	6 Months Ended
	Jun. 26, 2021	Dec. 26, 2020
Liabilities	$ 3,513,304,000	$ 3,460,448,000
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE	VIE is a trade accounts receivable securitization
Variable Interest Entity, Extent of or Lack of Recourse	The creditors have recourse to us for losses on these trade accounts receivable
Variable Interest Entity, Primary Beneficiary [Member] | Trade Accounts Receivable [Member]
Accounts Receivable	$ 0	0
Variable Interest Entity, Primary Beneficiary [Member] | Recourse [Member]
Liabilities	$ 0	$ 0

Critical Accounting Policies,_3

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards - Narrative (Details) - Accounting standard 2019-12 [Member]	Jun. 26, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Dec. 31, 2019

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Disaggregation of Revenue [Abstract]
Net sales		$ 2,967,223	$ 1,684,399	$ 5,892,184	$ 4,113,270
Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales		2,967,223	1,664,329	5,892,184	4,072,058
Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales	[1]	0	20,070	0	41,212
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales		2,135,277	1,205,461	4,267,124	2,985,359
North America [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales			1,205,461		2,985,359
North America [Member] | Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales			0		0
International [Member]
Disaggregation of Revenue [Abstract]
Net sales		831,946	478,938	1,625,060	1,127,911
International [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales			458,868		1,086,699
International [Member] | Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales			20,070		41,212
Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales	[2]	2,815,172	1,559,102	5,597,137	3,834,866
Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales	[2]	2,815,172	1,559,102	5,597,137	3,834,866
Healthcare Distribution [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		2,005,380	1,112,534	4,015,290	2,778,934
Healthcare Distribution [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		809,792	446,568	1,581,847	1,055,932
Healthcare Distribution [Member] | Dental [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales	[2]	1,910,344	941,292	3,699,272	2,416,368
Healthcare Distribution [Member] | Dental [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		1,127,607	515,946	2,172,390	1,404,318
Healthcare Distribution [Member] | Dental [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		782,737	425,346	1,526,882	1,012,050
Healthcare Distribution [Member] | Medical [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales	[2]	904,828	617,810	1,897,865	1,418,498
Healthcare Distribution [Member] | Medical [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		877,773	596,588	1,842,900	1,374,616
Healthcare Distribution [Member] | Medical [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Disaggregation of Revenue [Abstract]
Net sales		27,055	21,222	54,965	43,882
Technology [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales	[3]	152,051	105,227	295,047	237,192
Technology [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales		129,897	92,927	251,834	206,425
Technology [Member] | International [Member] | Total excluding Corporate TSA revenues [Member]
Disaggregation of Revenue [Abstract]
Net sales		$ 22,154	$ 12,300	$ 43,213	$ 30,767
[1]	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.
[2]	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins.
[3]	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 26, 2021	Dec. 26, 2020
Revenue from Contracts with Customers
Contract with Customer, Liability, Current	$ 70.9	$ 71.5
Contract with Customer, Liability, Noncurrent	9	$ 8.2
Contract with Customer, Liability, Revenue Recognized	$ 47.1

Segment Data (Details)

Segment Data (Details) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 26, 2021USD ($)segments	Jun. 27, 2020USD ($)	Jun. 26, 2021USD ($)segments	Jun. 27, 2020USD ($)
Segment Data
Number of reportable segments | segments				2
Segment Reporting Information [Line Items]
Net sales		$ 2,967,223	$ 1,684,399	$ 5,892,184	$ 4,113,270
Operating income		210,346	(7,433)	440,274	166,432
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Operating income		210,346	(7,433)	440,274	166,432
Total excluding Corporate TSA revenues [Member]
Segment Reporting Information [Line Items]
Net sales		2,967,223	1,664,329	5,892,184	4,072,058
Corporate TSA revenues [Member]
Segment Reporting Information [Line Items]
Net sales	[1]	$ 0	20,070	$ 0	41,212
Healthcare Distribution [Member]
Segment Reporting Information [Line Items]
Number of countries served globally | segments		32		32
Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member]
Segment Reporting Information [Line Items]
Net sales	[2]	$ 2,815,172	1,559,102	$ 5,597,137	3,834,866
Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Net sales	[2]	2,815,172	1,559,102	5,597,137	3,834,866
Operating income		181,761	(25,348)	379,693	122,819
Healthcare Distribution [Member] | Dental [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Net sales	[2]	1,910,344	941,292	3,699,272	2,416,368
Healthcare Distribution [Member] | Medical [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Net sales	[2]	904,828	617,810	1,897,865	1,418,498
Technology and Value-Added Services [Member] | Total excluding Corporate TSA revenues [Member]
Segment Reporting Information [Line Items]
Net sales	[3]	152,051	105,227	295,047	237,192
Technology and Value-Added Services [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Operating income		$ 28,585	$ 17,915	$ 60,581	$ 43,613
[1]	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.
[2]	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins.
[3]	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

Debt - Bank credit lines (Detai

Debt - Bank credit lines (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Line of Credit Facility [Line Items]
Bank Credit lines	$ 72,105	$ 73,366
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	0
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 72,105	$ 73,366

Debt - Revolving Credit Agreeme

Debt - Revolving Credit Agreement, 364-Day Credit Agreement and Other Short-Term Credit Lines Narrative (Details) - USD ($)	Mar. 04, 2021	Apr. 18, 2017	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Line of Credit Facility [Line Items]
Bank credit lines			$ 72,105,000		$ 73,366,000
Repayments of Long-term Debt			120,326,000	$ 609,580,000
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank credit lines			0		0
Revolving credit facility maturing in April 2022 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date		Apr. 18, 2017
Revolving credit facility borrowing capacity			750,000,000
Revolving credit facility expiration date		Apr. 30, 2022
Outstanding letters of credit provided to third parties			$ 9,300,000		9,500,000
364-day credit agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date			Apr. 17, 2020
Revolving credit facility expiration date			Apr. 16, 2021
Line of Credit Facility, Expiration Period			364 days
Repayments of Long-term Debt	$ 700,000,000
Various Bank Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines			$ 72,105,000		73,366,000
Other Short Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines			$ 72,100,000		$ 73,400,000
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)			5.98%		4.14%

Debt - Long-term Debt (Details)

Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Debt Instrument [Line Items]
Total long-term debt	$ 716,326	$ 625,609
Less current maturities	(9,839)	(109,836)
Total	706,487	515,773
Finance lease obligations (See Note 6)	5,701	5,961
Private placement facilities [Member]
Debt Instrument [Line Items]
Total long-term debt	706,332	613,498
Note payable [Member]
Debt Instrument [Line Items]
Total long-term debt	0	1,554
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.45% to 4.27% at June 26, 2021 and ranging from 2.62% to 4.27% at December 26, 2020 [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 4,293	$ 4,596
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.45% to 4.27% at June 26, 2021 and ranging from 2.62% to 4.27% at December 26, 2020 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	2.45%	2.62%
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.45% to 4.27% at June 26, 2021 and ranging from 2.62% to 4.27% at December 26, 2020 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	4.27%	4.27%

Debt - Private Placement Facili

Debt - Private Placement Facilities - Narrative (Details) $ in Billions	6 Months Ended
	Jun. 26, 2021USD ($)
Indebtedness ratio [Abstract]
Number of lenders	3
Private placement facilities [Member]
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity	$ 1
Debt Instrument, Interest Rate, Increase (Decrease)	1.00%
Indebtedness ratio [Abstract]
Average term of issuances under private placement facilities	12 years
Private placement facilities [Member] | Private placement facilities maturing in September 2030 [Member]
Indebtedness ratio [Abstract]
Debt instrument, maturity date	Sep. 2, 2030
Private placement facilities [Member] | Private placement facilities maturing in June 2031 [Member]
Indebtedness ratio [Abstract]
Debt instrument, maturity date	Jun. 2, 2031
Private placement facilities [Member] | Minimum [Member]
Indebtedness ratio [Abstract]
Term of issuances under private placement facilities	5 years
Private placement facilities [Member] | Maximum [Member]
Indebtedness ratio [Abstract]
Ratio of indebtedness to total capital	3.25
Ratio of Indebtedness to Net Capital	3
Term of issuances under private placement facilities	15 years

Debt - U.S. Trade Accounts Rece

Debt - U.S. Trade Accounts Receivable Securitization - Narrative (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 26, 2021	Dec. 26, 2020
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 716,326,000	$ 625,609,000
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Apr. 29, 2022
Debt instrument maximum borrowing capacity	$ 350,000,000
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.45%
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.25%
U.S. trade accounts receivable securitization [Member] | Extended Maturity [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	Jun. 12, 2023
U.S. trade accounts receivable securitization [Member] | Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 0	$ 0
Debt instrument, interest rate at period end	1.09%	1.17%
Debt instrument, variable rate basis at period end	0.14%	0.22%
Debt instrument, basis spread on variable rate	0.95%	0.95%

Debt - Private Placement Borrow

Debt - Private Placement Borrowings (Details) - USD ($) $ in Thousands	Jan. 20, 2016	Jun. 26, 2021	Dec. 26, 2020
Debt Instrument [Line Items]
Total long-term debt		$ 716,326	$ 625,609
Private placement facilities [Member]
Debt Instrument [Line Items]
Less: Deferred debt issuance costs		(811)
Total long-term debt		$ 706,332	$ 613,498
Private placement facilities [Member] | Private placement facilities maturing in January 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jan. 20, 2012
Long-term Debt, Gross		$ 7,143
Borrowing Rate		3.09%
Debt Instrument, Maturity Date		Jan. 20, 2022
Private placement facility, frequency of periodic payment		Annual
Private placement facility annual payment	$ 7,100
Debt Instrument, Date of First Required Payment		Jan. 20, 2016
Private placement facilities [Member] | Private placement facilities maturing in January 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jan. 20, 2012
Long-term Debt, Gross		$ 50,000
Borrowing Rate		3.45%
Debt Instrument, Maturity Date		Jan. 20, 2024
Private placement facilities [Member] | Private placement facilities maturing in December 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Dec. 24, 2012
Long-term Debt, Gross		$ 50,000
Borrowing Rate		3.00%
Debt Instrument, Maturity Date		Dec. 24, 2024
Private placement facilities [Member] | Private Placement facilities maturing in June 2027 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 16, 2017
Long-term Debt, Gross		$ 100,000
Borrowing Rate		3.42%
Debt Instrument, Maturity Date		Jun. 16, 2027
Private placement facilities [Member] | Private Placement facilities maturing in September 2029 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 15, 2017
Long-term Debt, Gross		$ 100,000
Borrowing Rate		3.52%
Debt Instrument, Maturity Date		Sep. 15, 2029
Private placement facilities [Member] | Private Placement facilities maturing in January 2028 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jan. 2, 2018
Long-term Debt, Gross		$ 100,000
Borrowing Rate		3.32%
Debt Instrument, Maturity Date		Jan. 2, 2028
Private placement facilities [Member] | Private placement facilities maturing in September 2030 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 2, 2020
Long-term Debt, Gross		$ 100,000
Borrowing Rate		2.35%
Debt Instrument, Maturity Date		Sep. 2, 2030
Private placement facilities [Member] | Private placement facilities maturing in June 2031 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 2, 2021
Long-term Debt, Gross		$ 100,000
Borrowing Rate		2.48%
Debt Instrument, Maturity Date		Jun. 2, 2031
Private placement facilities [Member] | Private Placement Facilities maturing in June 2033 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 2, 2021
Long-term Debt, Gross		$ 100,000
Borrowing Rate		2.58%
Debt Instrument, Maturity Date		Jun. 2, 2033

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Lessee, Lease, Description [Line Items]
Operating Lease, Payments	$ 39,988	$ 38,579
Building And Vehicles [Member]
Lessee, Lease, Description [Line Items]
Operating lease assets, Lease not yet commenced	$ 12,500
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating and finance lease, remaining lease term	1 year
Minimum [Member] | Building And Vehicles [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	2 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating and finance lease, remaining lease term	15 years
Maximum [Member] | Building And Vehicles [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Option to Extend	P10Y
Lessee, Finance Lease, Option to Extend	P10Y
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	10 years

Leases - Components of lease ex

Leases - Components of lease expense (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Leases
Operating lease cost	[1],[2]	$ 25,840	$ 21,991	$ 48,946	$ 44,070
Finance lease cost:
Amortization of right-of-use assets		516	282	1,120	714
Interest on lease liabilities		27	20	53	57
Total finance lease cost		$ 543	$ 302	$ 1,173	$ 771
[1]	Includes variable lease expenses.
[2]	Operating lease (credit) cost for the three months and nine months ended September 26, 2020, includes amortization of right-of-use assets of $(0.1) and $0.4 million, respectively, related to facility leases recorded in “Restructuring costs” within our consolidated statements of income.

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Operating Leases
Operating lease right-of-use assets	$ 301,440	$ 288,847
Current operating lease liabilities	75,008	64,716
Non-current operating lease liabilities	243,232	238,727
Total operating lease liabilities	318,240	303,443
Lessee, Finance Lease, Description [Abstract]
Property and equipment, at cost	11,443	10,683
Accumulated depreciation	(5,170)	(4,277)
Finance Leases	6,273	6,406
Current maturities of long-term debt	2,420	2,420
Long-term debt	3,281	3,541
Total finance lease liabilities	$ 5,701	$ 5,961
Operating Lease, Weighted Average Remaining Lease Term, in years	7 years 1 month 6 days	7 years 6 months
Finance Lease, Weighted Average Remaining Lease Term, in years	4 years	4 years 3 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	2.60%	2.80%
Finance Lease, Weighted Average Discount Rate, Percent	1.80%	1.90%

Leases - Supplemental cash flow

Leases - Supplemental cash flow information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 39,988	$ 38,579
Operating cash flows for finance leases	47	50
Financing cash flows for finance leases	1,407	947
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	49,226	14,926
Finance leases	$ 1,244	$ 1,814

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Operating Leases
2021	$ 42,284
2022	72,260
2023	49,569
2024	35,148
2025	30,519
Thereafter	118,761
Total future lease payments	348,541
Less imputed interest	(30,301)
Total operating lease liabilities	318,240	$ 303,443
Finance Leases
2021	1,384
2022	1,930
2023	963
2024	393
2025	337
Thereafter	895
Total future lease payments	5,902
Less imputed interest	(201)
Total finance lease liabilities	$ 5,701	$ 5,961

Leases - Present value of lease

Leases - Present value of lease liabilities (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Present value of lease liabilities - Operating Leases
Total future lease payments	$ 348,541
Less imputed interest	(30,301)
Total operating lease liabilities	318,240	$ 303,443
Present value of lease liabilities - Finance Leases
Total future lease payments	5,902
Less imputed interest	(201)
Total finance lease liabilities	$ 5,701	$ 5,961

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 327,699	$ 287,258	$ 287,258
Decrease in redeemable noncontrolling interests due to redemptions			(1,130)		(17,241)
Increase in redeemable noncontrolling interests due to business acquisitions			140,155		28,387
Net income attributable to Redeemable noncontrolling interests			14,033		13,363
Dividends declared			(9,954)		(12,631)
Effect of foreign currency translation loss attributable to redeemable noncontrolling interests	$ (6,743)	$ 751	(570)	$ (12,276)	(4,279)
Change in fair value of redeemable securities			132,708		32,842
Balance, end of period	$ 604,081		$ 604,081		$ 327,699

Comprehensive Income - Accumula

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (24,047)		$ (24,047)		$ (24,617)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	466		466		235
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(77,709)		(77,709)		(76,565)
Unrealized gain (loss) from foreign currency hedging activities	(9,878)		(9,878)		(11,488)
Unrealized investment gain (loss)	(2)		(2)		1
Pension adjustment gain (loss)	(19,190)		(19,190)		(20,032)
Accumulated other comprehensive income (loss)	(106,779)		(106,779)		(108,084)
Total Accumulated other comprehensive income (loss)	(130,360)		(130,360)		$ (132,466)
Components of comprehensive income [Abstract]
Net Income (loss)	163,977	$ (13,267)	338,905	$ 120,298
Foreign currency translation gain (loss)	38,138	34,408	(343)	(54,904)
Tax effect	0	0	0	0
Foreign currency translation gain (loss)	38,138	34,408	(343)	(54,904)
Unrealized gain (loss) from foreign currency hedging actiivities	(2,438)	(6,733)	2,257	13,500
Tax effect	687	1,744	(647)	(3,346)
Unrealized gain (loss) from foreign currency hedging activities	(1,751)	(4,989)	1,610	10,154
Unrealized investment gain (loss)	4	3	(4)	(8)
Tax effect	(1)	(1)	1	1
Unrealized investment gain (loss)	3	2	(3)	(7)
Pension adjustment gain (loss)	(3)	(350)	1,023	698
Tax effect	38	125	(181)	(199)
Pension adjustment gain (loss)	35	(225)	842	499
Comprehensive income	$ 200,402	$ 15,929	$ 341,011	$ 76,040

Comprehensive Income - Total Co

Comprehensive Income - Total Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 185,242	$ 17,600	$ 323,018	$ 87,586
Comprehensive income (loss) attributable to noncontrolling interests	1,437	(744)	3,390	(431)
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	13,723	(927)	14,603	(11,115)
Comprehensive income	$ 200,402	$ 15,929	$ 341,011	$ 76,040

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020	Dec. 28, 2019
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 604,081	$ 327,699	$ 287,258
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	2,788
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain] | Derivative contracts [Member]
Assets [Abstract]
Derivative contracts - assets	1,471	1,868
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Derivative contracts - assets	1,317	1,565
Fair value, measurements, recurring [Member]
Assets [Abstract]
Total assets	2,788	3,433
Liabilities [Abstract]
Derivative contracts - liabilities	9,542	11,765
Total liabilities	9,542	11,765
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	604,081	327,699
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain] | Derivative contracts [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member]
Assets [Abstract]
Derivative contracts - assets	0
Total assets		0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	2,788
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain] | Derivative contracts [Member]
Assets [Abstract]
Derivative contracts - assets	1,471	1,868
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Derivative contracts - assets	1,317	1,565
Fair value, measurements, recurring [Member] | Level 2 [Member]
Assets [Abstract]
Total assets		3,433
Liabilities [Abstract]
Derivative contracts - liabilities	9,542	11,765
Total liabilities	9,542	11,765
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain] | Derivative contracts [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member]
Assets [Abstract]
Total assets		0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	604,081	327,699
Fair value, measurements, recurring [Member] | Level 3 [Member] | Estimate of Fair Value Measurement [Member]
Debt Instrument, Fair Value Disclosure [Abstract]
Fair value of debt (including bank credit lines)	$ 788,400	$ 699,000

Business Acquisitions - Narrati

Business Acquisitions - Narrative (Details) - Acquisition in Health care or technology and value add services [Member]	Jun. 26, 2021
Minimum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	51.00%
Maximum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%

Business Acquisitions - Acquisi

Business Acquisitions - Acquisition consideration (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Acquisition consideration:
Initial noncontrolling interests and adjustments related to business acquisitions	$ 6,493	$ 4	$ 6,966	$ 4
Identifiable assets acquired and liabilities assumed:
Goodwill	2,722,974		2,722,974		$ 2,504,392
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Consideration paid for acquisitions			310,523
Initial noncontrolling interests and adjustments related to business acquisitions			129,319
Total consideration			439,842
Identifiable assets acquired and liabilities assumed:
Current assets	107,197		107,197
Intangible assets	183,796		183,796
Other noncurrent assets	33,959		33,959
Current liabilities	(43,781)		(43,781)
Deferred income taxes	(17,442)		(17,442)
Other noncurrent liabilities	(37,462)		(37,462)
Total identifiable net assets	226,267		226,267
Goodwill	213,575		213,575
Total net assets acquired	$ 439,842		$ 439,842

Plans of Restructuring - Narrat

Plans of Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 604	$ 15,934	$ 3,535	$ 20,721	$ 32,093

Plans of Restructuring - Restru

Plans of Restructuring - Restructuring Reserve Roll Forward by Expense and Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			$ 13,113	$ 13,810	$ 13,810
Provision	$ 604	$ 15,934	3,535	20,721	32,093
Payments and other adjustments			(13,007)		(32,790)
Restructuring Reserve, ending balance	3,641		3,641		13,113
Healthcare Distribution [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			12,824	13,373	13,373
Provision			3,082		30,935
Payments and other adjustments			(12,561)		(31,484)
Restructuring Reserve, ending balance	3,345		3,345		12,824
Technology and Value-Added Services [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			289	437	437
Provision			453		1,158
Payments and other adjustments			(446)		(1,306)
Restructuring Reserve, ending balance	296		296		289
Severance Costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			12,614	12,911	12,911
Provision			3,436		25,855
Payments and other adjustments			(12,736)		(26,152)
Restructuring Reserve, ending balance	3,314		3,314		12,614
Facility Closing Costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			395	826	826
Provision			(122)		5,878
Payments and other adjustments			50		(6,309)
Restructuring Reserve, ending balance	323		323		395
Other [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance			104	$ 73	73
Provision			221		360
Payments and other adjustments			(321)		(329)
Restructuring Reserve, ending balance	$ 4		$ 4		$ 104

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Weighted-average common shares outstanding:
Basic (in shares)	140,358	142,350	141,316	142,654
Effect of dilutive securities:
Restricted stock and restricted stock units	1,299	0	1,222	0
Diluted (in shares)	141,657	142,350	142,538	142,654

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Income Tax Examination [Line Items]
Unrecognized Tax Benefits, Interest on Income Taxes Expense	$ (2,700,000)	$ 1,800,000
Total penalties	$ 0		$ 0
Effective tax rate (in hundredths)	24.30%	24.20%
Other Liabilities [Member]
Income Tax Examination [Line Items]
Total interest	$ 11,300,000		$ 14,000,000
Unrecognized tax benefits that would affect the effective tax rate if recognized	63,900,000
Unrecognized tax benefits	$ 79,300,000

Derivatives and Hedging Activ_2

Derivatives and Hedging Activities - Narrative (Details) € in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 26, 2021USD ($)	Jun. 27, 2020USD ($)	Jun. 26, 2021USD ($)	Jun. 27, 2020USD ($)	Jun. 26, 2021EUR (€)	Jun. 26, 2021USD ($)	Mar. 20, 2020USD ($)
Total return swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount						$ 84.8	$ 43.4
Derivative, Inception Date			Mar. 20, 2020
Derivative, Description of Objective			we entered into a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities.
Derivative, Variable Interest Rate					0.56%	0.56%
Derivative, Gain on Derivative	$ 5.4	$ 6.7	$ 8.1	$ 10.3
Total return swap [Member] | London Interbank Offered Rate (LIBOR) Swap Rate [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Variable Interest Rate					0.09%	0.09%
Total return swap [Member] | Base Rate [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Basis Spread on Variable Rate					0.47%	0.47%
Foreign Exchange Forward [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Maximum duration of foreign currency forward contracts			18 months
Net Investment Hedging [Member] | Foreign Exchange Forward [Member] | Derivative contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Objectives for Using Net Investment Hedging Instruments			we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates.
Description of Net Investments Hedged			These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates.
Description of Location of Gain (Loss) on Net Investment Hedges in Financial Statements			Accumulated other comprehensive loss
Derivative, Maturity Date			Nov. 16, 2023
Derivative, Notional Amount | €					€ 200
Interest savings as a result of the net investment hedge.	$ 1.1	$ 1.2	$ 2.2	$ 2.4
Derivative, Type of Instrument			foreign currency forward contracts

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Disclosure of Stock-Based Compensation [Abstract]
Pre-tax share-based compensation (Credit) expense	$ 17,400,000	$ 5,200,000	$ 30,200,000	$ (12,400,000)
After-tax share-based compensation (credit) expense	13,300,000	$ 4,200,000	22,800,000	(9,400,000)
Excess Tax Benefit from Share-based Compensation, Financing Activities			0	$ 0
Total unrecognized compensation cost related to non-vested awards	$ 99,000,000		$ 99,000,000
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stock options vest per year			33.33%
Stock based compensation percentage of options vest per year first anniversary			50.00%
Stock based compensation percentage of options vest per year second anniversary			50.00%
Expected life of options (years)			6 years
2021 long-term incentive program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Time Based Restricted Stock Restricted Units [Member] | 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Performance Based Restricted Stock Restricted Units [Member] | 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Performance Based Restricted Stock Restricted Units [Member] | 2021 long-term incentive program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Stock-Based Compensation - Blac

Stock-Based Compensation - Black-Scholes valuation model (Details)	6 Months Ended
	Jun. 26, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend yield	0.00%
Expected stock price volatility	26.60%
Risk-free interest rate	0.94%
Expected life of options (years)	6 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of stock option activity (Details)	6 Months Ended
	Jun. 26, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares) | shares	0
Granted (in shares) | shares	794
Exercised (in shares) | shares	0
Forfeited (in shares) | shares	(2)
Outstanding at end of period (in shares) | shares	792
Weighted Average Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 0
Granted (in dollars per share)	62.82
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	62.71
Outstanding at end of period (in dollars per share)	$ 62.82
Weighted average remaining contractual life, options outstanding (in years)	9 years 8 months 12 days
Aggregate intrinsic value, options outstanding (in dollars per share)	$ 12.21
Options exercisable (in shares) | shares	1
Weighted average exercise price, options exercisable (in dollars per share)	$ 0
Aggregate intrinsic value, Options exercisable (in dollars per share)	$ 0

Stock-Based Compensation - Unve

Stock-Based Compensation - Unvested Resticted Stock/Units Activity (Details) shares in Thousands	6 Months Ended
	Jun. 26, 2021$ / sharesshares
Time Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	1,459
Granted (in shares) | shares	821
Vested (in shares) | shares	(266)
Forfeited (in shares) | shares	(19)
Ending balance outstanding (in shares) | shares	1,995
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 57.61
Granted (in dollars per share)	63.02
Vested (in dollars per share)	66.85
Forfeited (in dollars per share)	60.47
Ending balance outstanding (in dollars per share)	58.64
Aggregate intrinsic value	$ 75.01
Performance Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	136
Granted (in shares) | shares	286
Vested (in shares) | shares	(83)
Forfeited (in shares) | shares	(9)
Ending balance outstanding (in shares) | shares	330
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 53.52
Granted (in dollars per share)	58.60
Vested (in dollars per share)	52.30
Forfeited (in dollars per share)	59.46
Ending balance outstanding (in dollars per share)	59.50
Aggregate intrinsic value	$ 75.01

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Supplemental Cash Flow Information [Abstract]
Interest			$ 13,605	$ 16,925
Income taxes			134,232	31,553
Unrealized gain (loss) from foreign currency hedging activities	$ (2,438)	$ (6,733)	$ 2,257	$ 13,500

Legal Proceedings - Narrative (

Legal Proceedings - Narrative (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2021USD ($)claims	Jun. 27, 2020USD ($)	Jun. 26, 2021USD ($)claims	Jun. 27, 2020USD ($)	Dec. 26, 2020USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 2,967,223,000	$ 1,684,399,000	$ 5,892,184,000	$ 4,113,270,000
Loss Contingency, Management's Assessment and Process			As of June 26, 2021, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.
Archer and White Sales, Inc. v. collectively, the Danaher Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			August 31, 2012
Loss Contingency, Name of Defendant			Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”)
Loss Contingency, Name of Plaintiff			Archer and White Sales, Inc.
Loss Contingency, Allegations			Archer alleged a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights.
Archer filed amended complaint adding Patterson Companies Inc. and Benco Dental Supply Co. as Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			August 1, 2017
Loss Contingency, Name of Defendant			Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants
Loss Contingency, Name of Plaintiff			Archer
Loss Contingency, Allegations			alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer.
Archer filed second amended complaint under seal [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			October 30, 2017
Loss Contingency, Name of Plaintiff			Archer
Loss Contingency, Allegations			add additional allegations that it believes support its claims. The named parties and causes of action were the same as the August 1, 2017 amended complaint.
The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			May 29, 2018
Loss Contingency, Name of Defendant			adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants
Loss Contingency, Name of Plaintiff			The County of Summit, Ohio et al.
Loss Contingency, Allegations			Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs.
Loss Contingency, Settlement Agreement, Terms			On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation and paid $250,000 of Summit County’s expenses, as described in our prior filings with the SEC.
Donation amount to Pain Management Education Foundation			$ 1,000,000
Litigation Settlement, Amount Awarded to Other Party			$ 250,000
Actions consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Name of Defendant			Henry Schein and/or one or more of its affiliated companies
Loss Contingency, Allegations			allege claims similar to those alleged in the County of Summit Action
Actions consolidated in the MultiDistrict Litigation [Member] | Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number | claims	150		150
Maximum sales of opioids in North America during the year, percentage					0.10%
Actions consolidated in the MultiDistrict Litigation [Member] | Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues					$ 10,100,000,000
City of Hollywood Police Officers Retirement System V. Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			September 30, 2019
Loss Contingency, Name of Defendant			Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively
Loss Contingency, Name of Plaintiff			City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated
Loss Contingency, Allegations			Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading
Putative shareholder derivative action [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			February 5, 2021
Loss Contingency, Name of Defendant			Benjamin Shaw, Christine T. Komola, Steven Paladino, Betsy Atkins, Deborah G. Ellinger, Sandra L. Helton, Philip A. Laskaway, Mark J. Manoff, Edward M. McNamara, Ravi Sachdev, David E. Shaw, Benjamin Wolin, and Henry Schein, Inc., with Covetrus, Inc.
Loss Contingency, Name of Plaintiff			Jack Garnsey filed a putative shareholder derivative action on behalf of Covetrus, Inc.
Loss Contingency, Allegations			the individual defendants breached their fiduciary duties under state law in connection with the same allegations asserted in the City of Hollywood securities class action described above and further alleges that Henry Schein aided and abetted such breaches. The complaint also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants, also arising out of the allegations in the City of Hollywood lawsuit.
Period Of Time Action Is Stayed			45 days

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Henry Schein Animal Health Business [Member]
Related Party Transaction [Line Items]
Distributions to noncontrolling shareholders			$ 1,120
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $31.0 million annually for the use of their intellectual property.
Related Party Transaction, Amounts of Transaction	$ 7.8	$ 7.8	$ 15.6	$ 15.6
Related Party Transaction, Due from (to) Related Party	(6.3)		(6.3)		$ 4.7
Scenario, Plan [Member] | Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction			$ 31
Covetrus Inc [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a transition services agreement with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.
Related Party Transaction, Expenses from Transactions with Related Party		4.3		8.8
Revenue from Related Parties		20.1		41.2
Proceeds related to Animal Health Share Sale			$ 361.1
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Related Party Transaction, Purchases from Related Party	5.3	1.7	$ 9.1	4.5
Revenue from Related Parties	18	$ 9.1	33.4	$ 24.5
Due from Related Parties	42		42		36.4
Due to Related Parties	$ 10.1		$ 10.1		$ 8.6